Loading...
Loading...
Early In Thursday's pre-market session shares of Sarepta Therapeutics
SRPT have already dropped over 11 percent following an SEC filing from the company which stated the company's Senior Vice PResident and Chief Science Officer has been "terminated".
Following the filing biotech expert, Adam Feuerstein tweeted:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
